{"product_id":"roivant-business-model-canvas","title":"Roivant Sciences Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDecoding Roivant's Drug Development Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the core of Roivant Sciences's innovative approach to drug development with our comprehensive Business Model Canvas. This detailed breakdown reveals how they leverage strategic partnerships and a unique R\u0026amp;D model to accelerate therapeutic breakthroughs. Dive into the specifics of their value proposition and revenue streams to understand their competitive edge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences cultivates strategic alliances with established pharmaceutical titans to accelerate drug development and market penetration. These collaborations often involve co-commercialization efforts and intricate licensing deals, pooling resources and expertise.\u003c\/p\u003e\n\u003cp\u003eA prime illustration of this partnership strategy is Roivant's ongoing collaboration with Pfizer. This alliance is focused on advancing a novel TL1A-directed antibody, a promising therapeutic candidate, through Roivant's specialized 'Vant' subsidiary model.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences actively cultivates relationships with academic and research institutions, recognizing their vital role in pioneering early-stage research and drug discovery. These collaborations are instrumental in advancing scientific understanding and identifying novel therapeutic targets.\u003c\/p\u003e\n\u003cp\u003eA prime example of this strategic engagement is Roivant Social Ventures' partnership with the UNC Eshelman School of Pharmacy. This collaboration offers internship programs specifically designed to foster talent in drug development and explore innovative approaches to medicine access, directly contributing to Roivant's mission.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Research Organizations (CROs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eContract Research Organizations (CROs) are critical for Roivant Sciences, acting as external partners to manage and execute complex clinical trials. These collaborations enable Roivant to efficiently conduct studies, from identifying suitable patients to meticulously analyzing trial data, thereby speeding up the development of new medicines.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Roivant continued to lean on its CRO network to advance its broad portfolio. For instance, its subsidiary, Axovant Sciences, partnered with multiple CROs to conduct Phase 2 trials for its gene therapy candidate, AXO-AAV-GD, targeting GM2 gangliosidosis. This strategic outsourcing allows Roivant to maintain agility and focus on its core drug discovery and development strengths.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotechnology Companies (Vants)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoivant Sciences' core strategy hinges on its biotechnology company subsidiaries, known as Vants. These Vants act as crucial internal partnerships, each dedicated to a specific therapeutic area or drug development technology. This structure allows for a highly focused and agile approach to bringing new treatments to market.\u003c\/p\u003e\n\u003cp\u003eFor example, Immunovant, a Vant, is focused on developing therapies for autoimmune diseases, while Priovant targets inflammatory diseases. This model enables specialized expertise and dedicated resources, accelerating the development timeline for each program. As of early 2024, Roivant's portfolio includes several such Vants, each representing a significant internal collaboration.\u003c\/p\u003e\n\u003cp\u003eThese Vants are not merely operational units; they are integral to Roivant's business model, functioning as key partners in the scientific and commercialization process. This internal partnership framework is designed to optimize the management and advancement of diverse drug candidates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eVant Structure:\u003c\/strong\u003e Roivant establishes independent subsidiary companies (Vants) for specialized therapeutic areas or technologies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eKey Internal Partnerships:\u003c\/strong\u003e Vants like Immunovant and Priovant serve as critical internal collaborations for focused drug development.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAccelerated Development:\u003c\/strong\u003e This model facilitates specialized focus and expedited progress in bringing therapies to market.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Patient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoivant Sciences actively collaborates with healthcare providers to ensure its therapeutic innovations are clinically relevant and readily accessible to patients. This engagement is crucial for understanding the practical application of new treatments in real-world settings. For instance, in 2024, Roivant continued to build upon its network of clinical sites, with its portfolio companies conducting trials across numerous leading hospitals and specialized clinics globally.\u003c\/p\u003e\n\u003cp\u003ePartnerships with patient advocacy groups are fundamental to Roivant's strategy. These collaborations provide invaluable insights into unmet medical needs and help foster patient participation in clinical trials. By working with these groups, Roivant gains a deeper understanding of the patient journey and can better tailor its research and development efforts. In 2024, Roivant supported several patient-focused initiatives, aiming to increase awareness and access to novel therapies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eClinical Relevance:\u003c\/strong\u003e Partnerships with healthcare providers ensure Roivant's pipeline addresses current medical challenges and integrates seamlessly into existing care pathways.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient Access:\u003c\/strong\u003e Collaborations facilitate the distribution and adoption of Roivant's therapies once approved, improving patient outcomes.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eUnmet Needs:\u003c\/strong\u003e Patient advocacy groups offer critical perspectives on patient experiences and identify areas where new treatments are most needed.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTrial Engagement:\u003c\/strong\u003e These partnerships are vital for recruiting and retaining participants in clinical trials, accelerating drug development timelines.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances Drive Drug Development Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences leverages its Vant subsidiaries as crucial internal partners, each focusing on specific therapeutic areas or drug development technologies. These Vants, such as Immunovant for autoimmune diseases and Priovant for inflammatory conditions, allow for specialized expertise and dedicated resources, accelerating development timelines.\u003c\/p\u003e\n\u003cp\u003eExternal collaborations with major pharmaceutical companies, like the ongoing alliance with Pfizer for a TL1A-directed antibody, are vital for co-commercialization and licensing deals, pooling resources to advance promising candidates. Furthermore, partnerships with academic institutions and Contract Research Organizations (CROs) are essential for early-stage research, clinical trial execution, and data analysis, ensuring efficiency and agility in Roivant's drug development pipeline.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartnership Type\u003c\/th\u003e\n\u003cth\u003eKey Collaborators\u003c\/th\u003e\n\u003cth\u003eStrategic Importance\u003c\/th\u003e\n\u003cth\u003e2024 Focus\/Example\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmaceutical Giants\u003c\/td\u003e\n\u003ctd\u003ePfizer, others\u003c\/td\u003e\n\u003ctd\u003eCo-commercialization, licensing, resource pooling\u003c\/td\u003e\n\u003ctd\u003eAdvancing TL1A-directed antibody via Pfizer alliance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic\/Research Institutions\u003c\/td\u003e\n\u003ctd\u003eUNC Eshelman School of Pharmacy, etc.\u003c\/td\u003e\n\u003ctd\u003eEarly-stage research, novel target identification\u003c\/td\u003e\n\u003ctd\u003eInternship programs fostering drug development talent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract Research Organizations (CROs)\u003c\/td\u003e\n\u003ctd\u003eMultiple CROs\u003c\/td\u003e\n\u003ctd\u003eClinical trial management and execution\u003c\/td\u003e\n\u003ctd\u003eSupporting Phase 2 trials for AXO-AAV-GD by Axovant Sciences\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare Providers\u003c\/td\u003e\n\u003ctd\u003eLeading hospitals, specialized clinics\u003c\/td\u003e\n\u003ctd\u003eClinical relevance, patient access, real-world application\u003c\/td\u003e\n\u003ctd\u003eExpanding network of clinical sites for portfolio companies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Advocacy Groups\u003c\/td\u003e\n\u003ctd\u003eVarious patient groups\u003c\/td\u003e\n\u003ctd\u003eUnmet needs identification, patient trial participation\u003c\/td\u003e\n\u003ctd\u003eSupporting initiatives to increase awareness and access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA detailed breakdown of Roivant Sciences' strategy, outlining its core customer segments (patients and healthcare providers) and unique value propositions (accelerated drug development and de-risking). It covers key resources and activities, emphasizing their asset-centric approach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eRoivant Sciences' Business Model Canvas acts as a pain point reliever by offering a high-level, editable view of their complex drug development operations, allowing for quick identification of core components and strategic adaptation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Discovery and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences' core activity is the identification and advancement of novel drug candidates. This encompasses rigorous preclinical research and navigating the complex, multi-phase clinical trial process. The company focuses on critical therapeutic areas, including neurology, oncology, rare diseases, and endocrinology, aiming to bring innovative treatments to patients.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Roivant continued to advance its pipeline, with a particular emphasis on its neurology and oncology programs. For instance, its subsidiary, Axovant Sciences, is progressing a gene therapy for GM2 gangliosidosis, a rare neurological disorder. Another subsidiary, Dermavant Sciences, is developing treatments for inflammatory skin conditions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences' key activity involves the meticulous oversight and execution of clinical trials for its diverse pipeline. This ensures adherence to strict regulatory standards and facilitates timely data analysis, crucial for advancing drug development.\u003c\/p\u003e\n\u003cp\u003eThe company actively manages numerous pivotal trials, including those for promising candidates such as IMVT-1402 and brepocitinib. As of early 2024, Roivant has a substantial number of active clinical trials across various therapeutic areas, demonstrating its commitment to bringing new treatments to market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences' key activity involves expertly navigating the intricate regulatory landscape to gain approvals for its innovative therapies. This includes meticulous engagement with health authorities like the U.S. Food and Drug Administration (FDA) to ensure compliance and secure market authorization for new medicines.\u003c\/p\u003e\n\u003cp\u003eA prime example of this critical activity is the successful regulatory submission and subsequent approval of VTAMA (tapinarof) cream, 1% for the treatment of atopic dermatitis. This achievement underscores Roivant's capability in managing the complex process of bringing novel treatments from development to patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Marketing of Approved Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRoivant's commercialization and marketing efforts focus on successfully launching and promoting approved therapies, ensuring they reach the intended patient populations. This involves robust sales, marketing, and distribution strategies for their portfolio, including products like VTAMA.  For instance, VTAMA (tapinarof) cream, approved for plaque psoriasis, saw its first full year of commercialization in 2023, with net product sales reaching $119.7 million.  This demonstrates a key activity in bringing innovative treatments to market.\u003c\/p\u003e\n\u003cp\u003eThe company's approach includes building dedicated commercial teams and leveraging digital marketing channels to raise awareness among healthcare professionals and patients.  This strategic push aims to maximize market penetration and patient access.  Roivant's commitment to these activities is crucial for realizing the value of its pipeline and delivering on its mission to improve patient outcomes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eLaunch and Promotion:\u003c\/strong\u003e Executing comprehensive launch plans and ongoing promotional campaigns for approved therapies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSales and Distribution:\u003c\/strong\u003e Establishing efficient sales forces and distribution networks to ensure product availability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Access:\u003c\/strong\u003e Working to secure favorable reimbursement and formulary placement for therapies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient Engagement:\u003c\/strong\u003e Developing programs to support patients and improve adherence to treatment regimens.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Portfolio Management (Vant Model)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRoivant Sciences employs its distinctive 'Vant' model, a core strategic activity focused on building, financing, and managing a portfolio of independent biopharmaceutical companies. This approach allows for specialized focus and efficient resource allocation across diverse therapeutic areas.\u003c\/p\u003e\n\u003cp\u003eKey to this model is the strategic divestment of assets or entire Vants when they reach maturity or offer optimal value realization. This can involve sales, spin-offs, or initial public offerings, freeing up capital for reinvestment. For instance, in 2023, Roivant completed the spin-off of its dermatology business, Dermavant, to focus on its pipeline.\u003c\/p\u003e\n\u003cp\u003eThe capital generated from these strategic moves is then channeled back into research and development (R\u0026amp;D) for its remaining Vants, fueling innovation and the advancement of new therapies. Roivant’s commitment to R\u0026amp;D is substantial, with significant investments made annually to progress its pipeline. In fiscal year 2024, Roivant reported R\u0026amp;D expenses of approximately $650 million, underscoring its dedication to scientific advancement.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eVant Model Creation:\u003c\/strong\u003e Roivant establishes and funds specialized biopharmaceutical companies, each with its own management team and strategic direction.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Oversight:\u003c\/strong\u003e The company provides oversight and support to its Vants, ensuring alignment with Roivant's overall value creation strategy.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eValue Realization:\u003c\/strong\u003e Roivant strategically divests mature assets or entire Vants through various mechanisms to generate capital.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCapital Reinvestment:\u003c\/strong\u003e Proceeds from divestitures are reinvested into R\u0026amp;D for existing and new Vants, driving pipeline growth and innovation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvancing Biopharma: From Discovery to Market with Strategic Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences' key activities revolve around identifying promising drug candidates and advancing them through rigorous clinical development. This includes managing preclinical research and navigating the complex, multi-phase clinical trial process across therapeutic areas like neurology and oncology. In 2024, the company continued to advance its pipeline, with subsidiaries like Axovant Sciences progressing gene therapies and Dermavant Sciences developing treatments for inflammatory skin conditions.\u003c\/p\u003e\n\u003cp\u003eThe company's approach involves meticulous oversight and execution of clinical trials, ensuring adherence to regulatory standards and timely data analysis. Roivant manages numerous pivotal trials, including those for IMVT-1402 and brepocitinib, demonstrating a strong commitment to bringing new treatments to patients. As of early 2024, a significant number of active clinical trials underscore this dedication.\u003c\/p\u003e\n\u003cp\u003eNavigating the regulatory landscape is a critical activity, involving engagement with authorities like the FDA to secure market authorization. The successful approval of VTAMA (tapinarof) cream for atopic dermatitis exemplifies Roivant's capability in this area. Commercialization efforts focus on launching and promoting approved therapies, like VTAMA, which saw net product sales of $119.7 million in 2023, its first full year of commercialization.\u003c\/p\u003e\n\u003cp\u003eRoivant's distinctive 'Vant' model is a core strategic activity, focusing on building, financing, and managing a portfolio of specialized biopharmaceutical companies. This model facilitates efficient resource allocation and specialized focus. Strategic divestments of mature assets or entire Vants, such as the 2023 spin-off of Dermavant, generate capital for reinvestment in R\u0026amp;D. In fiscal year 2024, Roivant reported R\u0026amp;D expenses of approximately $650 million, highlighting its commitment to innovation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eKey Activity\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003e2024 Focus\/Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug Candidate Identification \u0026amp; Advancement\u003c\/td\u003e\n\u003ctd\u003eRigorous preclinical research and multi-phase clinical trial management.\u003c\/td\u003e\n\u003ctd\u003eAdvancing neurology and oncology programs; Axovant's GM2 gangliosidosis gene therapy.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Trial Execution\u003c\/td\u003e\n\u003ctd\u003eMeticulous oversight and adherence to regulatory standards.\u003c\/td\u003e\n\u003ctd\u003eManaging pivotal trials for IMVT-1402 and brepocitinib; numerous active trials.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Navigation \u0026amp; Approval\u003c\/td\u003e\n\u003ctd\u003eEngaging with health authorities for market authorization.\u003c\/td\u003e\n\u003ctd\u003eSuccessful approval of VTAMA (tapinarof) cream for atopic dermatitis.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercialization \u0026amp; Promotion\u003c\/td\u003e\n\u003ctd\u003eLaunching and promoting approved therapies to patient populations.\u003c\/td\u003e\n\u003ctd\u003eVTAMA net product sales reached $119.7 million in 2023.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e'Vant' Model Management\u003c\/td\u003e\n\u003ctd\u003eBuilding, financing, and managing specialized biopharmaceutical companies.\u003c\/td\u003e\n\u003ctd\u003eStrategic divestment of assets; FY24 R\u0026amp;D expenses approx. $650 million.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Business Model Canvas you are previewing is the exact document you will receive upon purchase. This comprehensive overview details Roivant Sciences' strategic approach to drug development, including key partners, value propositions, and revenue streams. You'll gain full access to this same professionally structured and insightful analysis, ready for your immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55611289633145,"sku":"roivant-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/roivant-business-model-canvas.png?v=1754754628","url":"https:\/\/growthsharematrix.com\/products\/roivant-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}